Monday, October 10, 2022 7:46:26 PM
Thank you for reposting that again. I believe that it is important to consider whether someone has a financial interest such as a short position, or whether they might have an interest as an investor in a competing company whenever they appear to exploit SEC filings to manufacture and publish disinformation. Without its full context, any isolated SEC disclosure is a gross distortion of reality and is misleading. SEC filings are reliable, but they are SEC filings.
Research what these documents are and what their purpose is. Compare the SEC filings for other pre-commercial biotech companies and for well-established commercial companies. By comparison, in context, and with an informed perspective, you can understand their content and their actual significance.
Who on Earth has any guarantees of future events or full control over the choices and decisions of others? Is there any valuable company with zero risk? Apple? Tesla? Amazon? Pfizer? Even the best and the biggest have risks to report. NWBO is not yet commercial, yet some seem to expect it to have fewer risks than a commercial giant?
SEC filings are solid sources. To ensure a proper and accurate understanding of their meaning, they must be read in full and in context. Furthermore, the publication date must be considered for perspective in light of subsequent developments and relevant new circumstances.
Compare any company’s filing to NVCR’s filing which lists pages and pages of risks to investors that perhaps, in an expert’s opinion, might appear much more severe than anything in the NWBO filing as a pre-commercial company. Why not consult an actual expert and compare the business outlook of both companies side-by-side? Just look at all the risks to their future business and investors that Novocure has buried in their filing:
https://d18rn0p25nwr6d.cloudfront.net/CIK-0001645113/c5eca622-306f-417f-931b-c2ab018fa6b6.pdf#page25
https://www.sec.gov/edgar/browse/?CIK=0001072379
https://www.merck.com/investor-relations/financial-information/sec-filings/
Research what these documents are and what their purpose is. Compare the SEC filings for other pre-commercial biotech companies and for well-established commercial companies. By comparison, in context, and with an informed perspective, you can understand their content and their actual significance.
Who on Earth has any guarantees of future events or full control over the choices and decisions of others? Is there any valuable company with zero risk? Apple? Tesla? Amazon? Pfizer? Even the best and the biggest have risks to report. NWBO is not yet commercial, yet some seem to expect it to have fewer risks than a commercial giant?
SEC filings are solid sources. To ensure a proper and accurate understanding of their meaning, they must be read in full and in context. Furthermore, the publication date must be considered for perspective in light of subsequent developments and relevant new circumstances.
Compare any company’s filing to NVCR’s filing which lists pages and pages of risks to investors that perhaps, in an expert’s opinion, might appear much more severe than anything in the NWBO filing as a pre-commercial company. Why not consult an actual expert and compare the business outlook of both companies side-by-side? Just look at all the risks to their future business and investors that Novocure has buried in their filing:
https://d18rn0p25nwr6d.cloudfront.net/CIK-0001645113/c5eca622-306f-417f-931b-c2ab018fa6b6.pdf#page25
https://www.sec.gov/edgar/browse/?CIK=0001072379
https://www.merck.com/investor-relations/financial-information/sec-filings/
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
